BHI CEO Rich Bendis recently served as an expert panelist contributing to a special report from the “White House Lab-to-Market Inter-Agency Summit.” Panelists examined the U.S. federal government’s investment in drug R&D and the resulting private sector commercialization. According to the Summit report: Federal research has done exceedingly well at accomplishing its original intent, which […]
BHI’s Rich Bendis Contributed to Special Report from White House Lab-to-Market Inter-Agency Summit
